Last reviewed · How we verify
OXY/APAP
OXY/APAP combines oxycodone (an opioid analgesic) with acetaminophen (a non-opioid analgesic) to provide enhanced pain relief through dual mechanisms.
OXY/APAP combines oxycodone (an opioid analgesic) with acetaminophen (a non-opioid analgesic) to provide enhanced pain relief through dual mechanisms. Used for Moderate to severe acute pain.
At a glance
| Generic name | OXY/APAP |
|---|---|
| Sponsor | Purdue Pharma LP |
| Drug class | Opioid analgesic combination |
| Target | Mu opioid receptor (oxycodone); COX inhibition and monoamine modulation (acetaminophen) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Oxycodone is a semi-synthetic opioid that binds to mu opioid receptors in the central nervous system to reduce pain perception and transmission. Acetaminophen works through distinct mechanisms including inhibition of prostaglandin synthesis and modulation of serotonergic and noradrenergic pathways. The combination provides synergistic analgesia, allowing lower opioid doses while maintaining efficacy and potentially reducing opioid-related adverse effects.
Approved indications
- Moderate to severe acute pain
Common side effects
- Nausea
- Constipation
- Dizziness
- Drowsiness
- Vomiting
- Pruritus
- Respiratory depression
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OXY/APAP CI brief — competitive landscape report
- OXY/APAP updates RSS · CI watch RSS
- Purdue Pharma LP portfolio CI